NYSE: PTN - Palatin Technologies, Inc.

Rentabilidade por seis meses: -42.28%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Palatin Technologies, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Palatin Technologies, Inc.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.

mais detalhes
In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 1993-10-28
ISIN US6960775020
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://palatin.com
Цена ао 0.7609
Alteração de preço por dia: 0% (0.7908)
Alteração de preço por semana: +2.37% (0.7725)
Alteração de preço por mês: -25.4% (1.06)
Alteração de preço em 3 meses: -4.84% (0.831)
Mudança de preço em seis meses: -42.28% (1.37)
Mudança de preço por ano: -50.58% (1.6)
Mudança de preço em 3 anos: +106.21% (0.3835)
Mudança de preço em 5 anos: +32.64% (0.5962)
Mudança de preço desde o início do ano: -8.05% (0.86)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 5.96 2
P/BV -239.91 0
P/E 0 0
EV/EBITDA -0.6135 0
Total: 4

Eficiência

Nome Significado Nota
ROA, % -207.35 0
ROE, % -263431.19 0
Total: 1.67

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0.0071

Obrigação

Nome Significado Nota
Debt/EBITDA -0.0203 10
Total: 10

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 3705.16 10
Rentabilidade Ebitda, % 23.01 4
Rentabilidade EPS, % -10.08 0
Total: 4
Mais detalhes

Instituições Volume Compartilhar, %
Armistice Capital, LLC 590000 3.66
Vanguard Group Inc 548622 3.4
LPL Financial LLC 146396 0.91
Blackrock Inc. 119518 0.74
Geode Capital Management, LLC 94148 0.58
State Street Corporation 30295 0.19
Susquehanna International Group, LLP 30062 0.19
Bridgeway Capital Management, Inc. 26124 0.16
Northern Trust Corporation 25097 0.16
Montis Financial, LLC 20964 0.13

ETFCompartilhar, %Rentabilidade para o ano, %Dividendos, %
iShares Micro-Cap ETF 0.00512 17.09 1.54048
0.0117.091.54



Supervisor Cargo Pagamento Ano de nascimento
Dr. Carl Spana Ph.D. Co-Founder, President, CEO & Director 979k 1962 (63 ano)
Mr. Stephen T. Wills CPA, MST CFO, COO, Executive VP, Treasurer & Secretary 910.55k 1957 (68 anos)
Burns McClellan Vice President of Investor Relations N/A
Mr. Stephen A. Slusher Esq. Chief Legal Officer N/A
Dr. Michael B. Raizman M.D. Chief Medical Officer N/A
Mr. James E. Hattersley Senior Vice President of Business Development N/A 1960 (65 anos)
Mr. John Dodd Ph.D. Senior Vice President of Preclinical Development N/A
Mr. Robert Jordan Senior Vice President of Program Operations N/A

Endereço: United States, Cranbury. NJ, Cedar Brook Corporate Center - abrir no Google Maps, abrir mapas Yandex
Site: https://palatin.com